Skip to Content

Banning Youth Use of Tanning Bed Would Be Cost-Effective

MONDAY, April 12, 2021 -- A tanning bed ban for U.S. minors would be cost-effective, according to a study published online April 12 in Cancer.

Antoine Eskander, M.D., from the University of Toronto, and colleagues modeled the potential health benefits and costs of banning tanning bed use by adolescents (aged 14 to 17 years).

The researchers found that full adherence to the ban prevented 15,102 melanoma cases and 3,299 recurrences among 17.1 million minors, saving $342.9 million in treatments costs over the lifetime of 61.2 million youth and providing an increase of 0.0002 quality-adjusted life years. A ban remained the dominant strategy despite the intervention costs of the ban and the economic losses to the indoor-tanning industry, with a savings of $12 per minor and $205.4 million among 17.1 million minors. For varying inspection costs and ban compliance, the findings remained robust, but were sensitive to a lower excess risk for melanoma with early exposure to tanning beds.

"When balancing measures are accounted for in an extended societal perspective analysis, even with extensive sensitivity analyses on the costs of inspections, noncompliance with a ban, and the risk of developing melanoma in those who have used tanning beds, a ban can be considered highly cost-effective," the authors write.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Sunburns Severe Enough to Warrant Admission Described

WEDNESDAY, May 12, 2021 -- Sunburns severe enough to warrant admission to a specialist burn service are described in a research letter published online May 12 in JAMA...

Many Americans Wrong About Sun's Skin Cancer Dangers: Poll

TUESDAY, May 4, 2021 -- A new survey reveals that one-third of Americans lack a basic understanding of sun safety and skin cancer. That is the surprising takeaway from an American...

Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common

FRIDAY, April 16, 2021 -- Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.